Article
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2025
Goyal L, DiToro D, Hollebecque A, Bridgewater J A, Shimura M, Kano A, Okamura S, Silhavy J L, Wacheck V, Halim A, Meric-Bernstam F
Abstract excerpt
BACKGROUND: Futibatinib is the only covalent inhibitor of FGFR1-4 to gain regulatory approval in oncology. In this article, we present genomic analyses of tissue biopsies and circulating tumor DNA (ctDNA) from patients with 1 of nearly 20 tumor types treated with futibatinib in the phase I/II FOENIX study. PATIENTS AND METHODS: Eligible patients included those with ctDNA samples collected per protocol at baseline...
Topics
Join the communities discussing this publication.